Klotho Neurosciences, Inc. (KLTO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
13576 Walnut Street
Omaha, NE 68144
United States of America (the)
Phone
833 931 6330
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3
First IPO Date
April 29, 2022
| Name | Title | Pay | Year Born |
| Joseph Sinkule | Founder, Chief Executive Officer, Chairman of the Board & Secretary | 480,000 | 1954 |
| Shalom Z. Hirschman | Medical Advisor & Director | 120,000 | 1936 |
| Peter J. Moriarty | Chief Business Officer | 172,500 | 1950 |
| Jeffrey LeBlanc | Chief Financial Officer | 401,506 | 1973 |
| Miguel Chillon Rodriguez | Chief Scientific Officer & Consultant | 0 | 1966 |
Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024. The firm's main office is situated in Omaha, Nebraska.